DAESUNG MICROBIOLOGICAL LABS. CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,570 KRW | +0.28% |
|
+1.44% | -3.47% |
| Sales 2022 | 25.5B 18.54M 25.3M | Sales 2023 | 25.56B 18.58M 25.36M | Capitalization | 41.61B 30.25M 41.28M |
|---|---|---|---|---|---|
| Net income 2022 | 1.7B 1.24M 1.69M | Net income 2023 | -680M -494K -675K | EV / Sales 2022 | 1.89 x |
| Net Debt 2022 | 9.17B 6.67M 9.1M | Net Debt 2023 | 12.28B 8.93M 12.19M | EV / Sales 2023 | 2.11 x |
| P/E ratio 2022 |
23
x | P/E ratio 2023 |
-61.2
x | Employees | 134 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.4% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.28% | ||
| 1 week | +1.44% | ||
| Current month | +0.38% | ||
| 1 month | +0.28% | ||
| 3 months | -1.31% | ||
| 6 months | -9.66% | ||
| Current year | -3.47% |
1 week
10 420.00
10 700.00
1 month
10 120.0012 690.00
Current year
10 120.0012 690.00
1 year
9 690.0019 450.00
3 years
9 680.0023 700.00
5 years
8 010.0027 250.00
10 years
3 790.0029 900.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hang-Won Cho
CEO | Chief Executive Officer | 70 | 98-08-31 |
Dong-Kyu Lee
CEO | Chief Executive Officer | 65 | 81-01-31 |
Dong-Jik Lee
BRD | Director/Board Member | 70 | 78-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dong-Kyu Lee
CEO | Chief Executive Officer | 65 | 81-01-31 |
Hang-Won Cho
CEO | Chief Executive Officer | 70 | 98-08-31 |
Dong-Heon Kwon
BRD | Director/Board Member | 66 | 08-02-29 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 10,570 | +0.28% | 8,890 |
| 24-04-25 | 10,540 | -0.94% | 13,042 |
| 24-04-24 | 10,640 | +0.47% | 28,275 |
| 24-04-23 | 10,590 | +1.34% | 29,907 |
| 24-04-22 | 10,450 | +0.29% | 16,253 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
DAESUNG MICROBIOLOGICAL LABS. CO., LTD. is a Korea-based company mainly engaged in the manufacture of animal pharmaceuticals. The Companyâs products consist of vaccines, antibiotics, antibacterials, anthelminthics, mastitis ointments, disinfectants, probiotics and enzyme products, teat dipping disinfectants, metabolites, nutrients, and biologicals used for prevention and treatment of diseases for cattle, swine, poultries and canines. The Company distributes its products within domestic market and to overseas markets, including Southeast Asia, Middle East and Africa.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -3.47% | 29.18M | |
| -18.14% | 72.39B | |
| -7.52% | 6.54B | |
| +15.88% | 3.43B | |
| +1.18% | 1.4B | |
| -17.27% | 1.34B | |
| -3.81% | 1.26B | |
| -28.16% | 1.2B | |
| -14.67% | 1.12B | |
| -5.37% | 990M |
- Stock Market
- Equities
- A036480 Stock
